These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18260885)

  • 1. [Perspectives of the use of antihyperglycemic preparations in patients with metabolic syndrome and prediabetes].
    Mamedov MN; Shishkova VN
    Kardiologiia; 2007; 47(6):88-93. PubMed ID: 18260885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
    Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
    Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy in prediabetes.
    Mukhopadhyay P; Chowdhury S
    J Indian Med Assoc; 2005 Nov; 103(11):603-5, 608. PubMed ID: 16570765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
    Smith-Marsh D
    Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of incretin-based therapies in prediabetes: a review.
    Ahmadieh H; Azar ST
    Prim Care Diabetes; 2014 Dec; 8(4):286-94. PubMed ID: 24666932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice.
    Gao LH; Liu Q; Liu SN; Chen ZY; Li CN; Lei L; Sun SJ; Li LY; Liu JL; Shen ZF
    J Ethnopharmacol; 2014; 151(1):675-85. PubMed ID: 24286962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycemic, antihyperglycemic, and antioxidant effects of the edible plant Anoda cristata.
    Juárez-Reyes K; Brindis F; Medina-Campos ON; Pedraza-Chaverri J; Bye R; Linares E; Mata R
    J Ethnopharmacol; 2015 Feb; 161():36-45. PubMed ID: 25490313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic implications of diabetes in cardiovascular disease.
    Cherian B; Meka N; Katragadda S; Arora R
    Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of prediabetes.
    Priya G
    J Pak Med Assoc; 2018 Apr; 68(4):669-671. PubMed ID: 29808066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Syndrome: Insulin Resistance and Prediabetes.
    Mayans L
    FP Essent; 2015 Aug; 435():11-6. PubMed ID: 26280340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.
    Hostalek U; Gwilt M; Hildemann S
    Drugs; 2015 Jul; 75(10):1071-94. PubMed ID: 26059289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome.
    Devaraj S; Yimam M; Brownell LA; Jialal I; Singh S; Jia Q
    Metab Syndr Relat Disord; 2013 Feb; 11(1):35-40. PubMed ID: 23035844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired glucose tolerance and impaired fasting glucose.
    Rao SS; Disraeli P; McGregor T
    Am Fam Physician; 2004 Apr; 69(8):1961-8. PubMed ID: 15117017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
    Hanefeld M
    Cardiovasc Diabetol; 2007 Aug; 6():20. PubMed ID: 17697384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.